文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

卡瑞利珠单抗联合化疗一线治疗晚期或转移性食管鳞癌的ESCORT-1st随机临床试验

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

ESCORT-1st是一项在中国60家医院开展的随机双盲安慰剂对照3期试验,纳入596例未经治疗的晚期或转移性食管鳞癌患者,比较卡瑞利珠单抗或安慰剂联合紫杉醇和顺铂的疗效与安全性。

要点

  • 卡瑞利珠单抗联合化疗显著延长晚期食管鳞癌患者总生存期(15.3 vs 12.0个月,HR 0.70)。
  • 联合组无进展生存期亦显著改善(6.9 vs 5.6个月,HR 0.56)。
  • ≥3级治疗相关不良事件发生率联合组63.4%,安慰剂组67.7%。

核心结论

  • 在晚期或转移性食管鳞癌患者中,与安慰剂联合化疗相比,卡瑞利珠单抗联合化疗显著改善总生存期和无进展生存期。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心3期试验(ESCORT-1st),中国60家医院,2018年12月3日至2020年5月12日入组,最终随访2020年10月30日。
  • 筛查751例,随机596例未经治疗的晚期或转移性食管鳞癌患者,1:1分配至卡瑞利珠单抗200 mg组(n=298)或安慰剂组(n=298),联合最多6周期紫杉醇(175 mg/m2)和顺铂(75 mg/m2),每3周静脉给药。

主要发现

  • ≥3级治疗相关不良事件:卡瑞利珠单抗-化疗组189例(63.4%),安慰剂-化疗组201例(67.7%);治疗相关死亡分别为9例(3.0%)和11例(3.7%)。

临床怎么用

  • 对于未经治疗的晚期或转移性食管鳞癌患者,可考虑卡瑞利珠单抗联合紫杉醇和顺铂作为一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced or metastatic esophageal squamous cell carcinoma. OBJECTIVE: To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as a first-line treatment in advanced or metastatic esophageal squamous cell carcinoma. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (ESCORT-1st study) enrolled patients from 60 hospitals in China between December 3, 2018, and May 12, 2020 (final follow-up, October 30, 2020). A total of 751 patients were screened and 596 eligible patients with untreated advanced or metastatic esophageal squamous cell carcinoma were randomized. INTERVENTIONS: Patients were randomized 1:1 to receive either camrelizumab 200 mg (n = 298) or placebo (n = 298), combined with up to 6 cycles of paclitaxel (175 mg/m2) and cisplatin (75 mg/m2). All treatments were given intravenously every 3 weeks. MAIN OUTCOMES AND MEASURES: Coprimary end points were overall survival (significance threshold, 1-sided P < .02) and progression-free survival (significance threshold, 1-sided P < .005). RESULTS: Of the 596 patients randomized (median age, 62 years [interquartile range, 56-67 years]; 523 men [87.8%]), 1 patient in the placebo-chemotherapy group did not receive planned treatment. A total of 490 patients (82.2%) had discontinued the study treatment. The median follow-up was 10.8 months. The overall survival for the camrelizumab-chemotherapy group was a median of 15.3 months (95% CI, 12.8-17.3; 135 deaths) vs a median of 12.0 months (95% CI, 11.0-13.3; 174 deaths) for the placebo-chemotherapy group (hazard ratio [HR] for death, 0.70 [95% CI, 0.56-0.88]; 1-sided P = .001). Progression-free survival for camrelizumab plus chemotherapy was a median of 6.9 months (95% CI, 5.8-7.4; 199 progression or deaths) vs 5.6 months (95% CI, 5.5-5.7; 229 progression or deaths) for the placebo-chemotherapy group (HR for progression or death, 0.56 [95% CI, 0.46-0.68]; 1-sided P < .001). Treatment-related adverse events of grade 3 or higher occurred in 189 patients (63.4%) in the camrelizumab-chemotherapy group and 201 (67.7%) in the placebo-chemotherapy group, including treatment-related deaths among 9 patients (3.0%) and 11 patients (3.7%), respectively. CONCLUSIONS AND RELEVANCE: Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03691090.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021. PMID: 34519801. doi:10.1001/jama.2021.12836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。